June 23, 2020 / 12:21 PM / 14 days ago

BRIEF-Kadmon Doses First Patient In Phase 1 Clinical Trial To Treat Advanced Solid Tumors

June 23 (Reuters) - Kadmon Holdings Inc:

* KADMON DOSES FIRST PATIENT IN PHASE 1 CLINICAL TRIAL OF KD033, ANTI-PD-L1/IL-15 FUSION PROTEIN, IN ADULTS WITH METASTATIC/LOCALLY ADVANCED SOLID TUMORS Source text: [ID:bit.ly/3esPz38] Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below